Replimune ($REPL): What Does the TUDRIQEV Launch Have to Deliver Against the Hercules Covenant?

01 Bull, bear and base after FDA approval

The bull argument

• Broad post-PD-1 label without an explicit requirement for prior CTLA-4 therapy.
• A differentiated outpatient intratumoral option in a population with limited treatment choices.
• Ability to inject superficial and deep or visceral lesions expands practical reach.
• Existing physician experience from more than 1,000 injections and concentrated launch focus may shorten activation.
• Approval improves financing leverage and validates the RPx platform.
• IGNYTE-3 can convert accelerated approval into durable evidence while RP2 adds pipeline optionality.

The bear argument

• The label efficacy set is smaller and less impressive than the full-cohort figures used in the pre-approval narrative.
• Repeated intratumoral procedures, nivolumab coordination and image guidance may slow adoption.
• August financing alleviated the reported going-concern doubt; launch spending, debt and potential ATM use retain future funding and dilution risk.
• The April restructuring removed the in-house commercial organization described in the 10-K.
• IGNYTE-3 can fail to verify benefit or take longer than expected, threatening continued approval.
• Competition from TIL therapy, checkpoint combinations and other melanoma approaches may limit share.

A reasonable base description

Approval removes the largest immediate downside branch, but it does not yet prove a successful franchise. A base case is a measured launch concentrated in experienced melanoma centers, supported by the completed August financing, with a period in which account activation and early patient starts matter more than headline response data. The quality of the equity story improves materially if management can show reimbursement traction, manageable gross-to-net economics, controlled cash burn and steady IGNYTE-3 progress.

What Would Falsify This Reading

This page reads Replimune as a company that has crossed from regulatory risk to commercial and financing risk: the product is approved, the confirmatory obligation is outstanding, and the balance sheet was rescued rather than built. Each of the following would contradict that reading directly, and each is checkable against a primary document.

• IGNYTE-3 does not verify the benefit. TUDRIQEV was approved on an accelerated basis, and the confirmatory obligation sits on the company. A confirmatory trial that fails, or that cannot be completed, unwinds an approval rather than merely disappointing.
• The Hercules covenant binds. Once the outstanding principal under the term loan facility reaches $100.0 million, the company must satisfy one of three tests: minimum trailing three-month net product revenue tested monthly, a market capitalisation above $1.2 billion with unrestricted cash of at least half the exposure, or unrestricted cash of at least 85% of it. The Finviz market capitalisation read October 2, 2026 was about $1.28 billion. That is not a breach and it is not a forecast; it is a number to watch against a documented threshold.
• The launch does not produce the revenue the covenant contemplates. The first of those three tests is a revenue test. A launch that is slower than the company expects makes the other two tests, both of which are about cash and market value, the ones that matter.
• The authorised-share increase is used. Shareholders doubled authorised common stock to 300,000,000 on September 15, 2026, against 94,219,634 shares outstanding at August 11. Authorisation is capacity, not issuance. An equity raise that uses a material part of it, after the August raise of about $141.0 million net, would say the commercial ramp is not funding the company.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

02 Contents

03 The thesis after approval

Replimune develops tumor-directed oncolytic immunotherapies based on engineered herpes simplex virus type 1. On August 6, 2026, its lead asset moved from development code to approved product: RP1 became TUDRIQEV (vusolimogene oderparepvec-wtpg), used with nivolumab in adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking antibody-based regimen.

The approval is strategically transformative. Replimune is no longer underwriting only regulatory probability; it must now manufacture, distribute, secure reimbursement and drive adoption for a first commercial product. The broad post-PD-1 label creates a real opportunity in a population with limited options, including patients with superficial and visceral disease, but launch execution becomes the immediate proof point.

The FDA resolved the immediate approval question through the accelerated pathway, not through a finding that every methodological concern had disappeared. The agency restricted the efficacy-evaluable set to patients with a noninjected lesion and tied continued approval to confirmation of clinical benefit. That preserves the central role of the randomized IGNYTE-3 trial.

The commercial proposition has attractions and frictions. TUDRIQEV can be injected into superficial and deep/visceral lesions and avoids the tumor-harvest, lymphodepletion and inpatient logistics associated with TIL therapy. However, it still requires repeated intratumoral administration every two weeks, nivolumab, image guidance for deeper disease and coordination between oncology and interventional radiology.

FDA accelerated approval has shifted the focus to launch execution. The June-quarter 10-Q is now filed: August financing alleviated the reported going-concern doubt and approval extended Hercules maturity to October 2029. IGNYTE-3 remains essential to continued approval. SEC · 10-Q, 2026-08-14

The investable question has therefore changed from “Will FDA approve?” to three measurable questions: how quickly accounts activate, whether reimbursement and procedural logistics support adoption, and whether IGNYTE-3 confirms clinical benefit before liquidity pressure forces highly dilutive financing.

04 The full regulatory sequence, through approval

The chronology matters more than any single event, because the pattern is what carries information. Every line below is drawn from a filing or a company release.

Two things stand out from the table alone. The company has been in continuous regulatory process on this single application for roughly twenty months. And the review classification moved in the opposite direction to what you would expect: the second submission was treated as a Class 2, six-month review; the third, after a rejection, was treated as a Class 1, two-month review.

05 What the second CRL actually says — the FDA’s own words

The FDA has published the Complete Response Letter for BLA 125827, dated April 10, 2026, in full on its open data repository. This is the agency’s own document, not a summary of it, and it settles several disputes about what happened.

Who decided, and how

On the change of review team, which Replimune presented to shareholders as a grievance, the letter is explicit about the reason:

And on the decision itself:

The letter also states: “FDA advice has remained consistent as evidenced by our communications dating back to March 2021 and subsequent interactions described in this letter.”

Three of the company’s public contentions do not survive contact with this document. The team was changed deliberately, for objectivity, not arbitrarily. The determination was unanimous across the clinical reviewers, supervisory leadership and the Oncology Center of Excellence — not a leadership override of a supportive clinical team. And the agency asserts that its advice has been consistent since 2021, rather than reversed after the Type A meeting.

The finding that matters most for the numbers

The letter dismantles the headline response rate from the inside. RP1 is injected directly into tumours, so the whole question is whether the tumours that shrank were the ones that received the injection, or others elsewhere in the body. On that:

“FDA review identified that almost half (49%) of the patients with objective response had all their target lesions injected with vusolimogene oderparepvec. Furthermore, FDA review identified two additional patients deemed responders who did not have any target lesions per independent review at baseline. Thus, over half (53%) of patients with objective response did not have noninjected target lesions to assess systemic anti-tumor activity.”

“When these patients are excluded from the analysis of the primary endpoint of ORR, the resulting response rate decreases markedly from your reported response rate in RPL-001-16.”

More than half of the responses on which the application rests cannot demonstrate that the drug did anything beyond the site of injection. Strip them out and the response rate falls “markedly” — the FDA does not give the adjusted figure in the public version, but it does not need to.

Three further problems with how responses were counted

• Re-injection before progression was declared. The FDA found patients with new lesions, or with existing lesions that had enlarged, who were re-injected before the independent review committee had determined progressive disease. The letter says this would confound “both the reported response rate (by counting responses that occurred after progression) and the reported duration of response (by extending the duration beyond progression events).” That is a direct attack on the 33.7-month median duration of response.
• Surgery on target lesions. Surgical procedures including excisional biopsies were performed on target lesions during treatment and “in some cases, immediately preceded the next response assessment that determined a partial or complete response.” The FDA’s point is blunt: the tumour may have got smaller because a surgeon removed part of it.
• Histology not centrally reviewed. Pathology results were used to assess response and in some cases changed the radiological assessment of best overall response. Those specimens were not centrally reviewed, and the FDA flags sampling bias and the difficulty of telling a local injection-site effect from a systemic one.

The RECIST question, answered

Replimune told shareholders that responses were assessed “using RECIST 1.1 without modifications.” The FDA letter says the opposite twice: that at the September 16, 2025 Type A meeting it communicated that “the response criteria used in RPL-001-16 were not consistent with RECIST v1.1 and may not be comparable to response rates reported in the historical literature”, and that “review of the individual patient data also revealed multiple deviations from standard RECIST v1.1 methodology.”

What was submitted from the Phase 3, and why it did not help

To support the October 2025 resubmission the company provided an early unplanned analysis from the ongoing randomized Phase 3, RP1-104: 22 patients in the RP1 plus nivolumab arm and 18 in the control arm — 40 patients, or 10% of the planned 400. The FDA listed four deficiencies: the limited number treated, response assessment by investigator only, lack of duration of response data, and progression-free survival that could not be interpreted “due to lack of prespecification for this analysis and without adequate type 1 error control.”

The advice was given in 2021

The letter reproduces what the FDA told Replimune at a Type B meeting on March 25, 2021 — five years before the second rejection:

• “your proposed single-arm study will not enable identification of the contribution of each component of the combination to the overall response rate”, with a recommendation to run a randomized controlled trial;
• “your proposed target of 30% to 40% objective response rate (ORR) may not translate into unequivocally improved clinical benefit in this indication”;
• concern about “potential issues of interpreting efficacy result due to baseline heterogeneities among study subjects”, and that the agency “would not recommend that the Sponsor submit a BLA based on the results of a single-arm study”;
• “we consider the interpretation of responses in the setting of the intra-tumoral route of administration to be problematic in the lesions which have been injected.”

On the company’s argument that the FDA had blessed the filing, the letter concedes the point and reframes it: “FDA ultimately did not object to the submission of the BLA based on data from RPL-001-16, reflecting FDA’s flexibility in disease settings with high unmet need. However, on review of the RPL-001-16 data submitted to support the BLA, the study design concerns previously communicated were not addressed.” Not objecting to a filing is not the same as agreeing that the filing will succeed.

What the FDA demanded, and what it offered

The requirement: “To address these deficiencies, you must conduct and provide the results from adequate and well-controlled clinical trial(s) which demonstrate substantial evidence of effectiveness.” The offer, in the closing paragraphs: “You may request a meeting to discuss if the ongoing RP1-104 study with a revised study protocol and statistical analysis plan can address the deficiencies outlined, or propose a new clinical study.”

06 The reversal: May 29 and June 26

Seven weeks after that letter, the tone changed completely. On May 29, 2026 Replimune announced that it and the FDA had “aligned on a path forward for resubmission and reconsideration” and that the agency “will treat the BLA resubmission as an urgent matter upon receipt and will prioritize its review.” The shares rose roughly 80% that day.

On June 26 the acceptance arrived on terms more favorable than the company could reasonably have expected: a class 1 classification, meaning the two-month clock, with a goal date of August 2, 2026. The company framed it as the FDA having “demonstrated urgency in reconsidering the RP1 BLA with an expeditious action date in recognition of the significant unmet need.” In the same sentence came the qualifier: the FDA had “notified the company to expect an advisory committee meeting in late July.”

Why the classification is the odd part

Resubmissions after a Complete Response Letter are classified by how much new review they require. Class 1 is the two-month category for responses the agency considers relatively minor — final printed labeling, safety updates, stability data, minor reanalyses, post-marketing commitments. Class 2 is six months and covers anything needing substantive new review, including new clinical data.

The October 2025 resubmission, which added an early Phase 3 analysis, was classified Class 2. This one, following a rejection that demanded adequate and well-controlled trials, was classified Class 1 — and an advisory committee, the most resource-intensive instrument the agency has for a single application, was attached to the lighter, faster category.

07 What changed between April and May: leadership, process and the panel record

The obvious question after the unanimous April rejection was what happened between April 10 and the FDA’s agreement on May 29 to reconsider the file urgently. Neither the company nor the FDA has provided a complete primary-document explanation. Reporting at the time connected the reversal to changes in senior FDA leadership and intervention by administration officials, while also reporting that government lawyers found no procedural defect that compelled a different scientific conclusion.

That context remains relevant, but the July 30 vote changes the evidentiary picture in an important way. Before the meeting, the most skeptical reading was that the third review reflected a political or institutional decision imposed above a career review staff that remained opposed. The FDA briefing document confirmed that the staff’s scientific position had not softened: it continued to challenge response assessment, contribution of effect, historical controls and interpretation of overall survival.

The panel then voted 10–3 in Replimune’s favor on evaluability and clinical meaningfulness. That outcome means the third review can no longer be described only as a political reprieve unsupported by outside scientific judgment. A clear majority of independent voting experts looked at the same central dispute and concluded that the efficacy package could be evaluated and was clinically meaningful.

That split is now the institutional fact the FDA must resolve. If the agency approves, it can point to the panel’s clinical judgment, unmet need, durability and confirmatory trial as support for regulatory flexibility. If it rejects again, it must do so against a 10–3 public vote that the efficacy results are both evaluable and clinically meaningful.

08 Why the July 30 panel vote mattered

The July 30 CTGTAC vote was not approval, but it was the decisive bridge to the August 6 outcome. The panel voted 10 Yes, 3 No and 0 Abstain on the question: “Are the efficacy results from IGNYTE evaluable and clinically meaningful?”

That wording directly addressed the review division’s central objection. FDA staff had argued that the single-arm design, injected target lesions, procedures affecting response assessment and inability to isolate RP1’s contribution made the dataset unreliable. A strong majority of outside experts accepted that the clinical signal was still interpretable and meaningful in a high-unmet-need setting.

The final label shows how FDA translated that compromise into an approval. Rather than use the full 140-patient response estimate, the prescribing information defines an efficacy population of 91 patients with at least one noninjected lesion. That approach preserved a measurable systemic-efficacy signal while addressing the most damaging concern about directly injected target lesions.

The vote did not make the methodological dispute irrelevant; it made a narrower regulatory solution possible. The agency accepted accelerated approval while using a more conservative efficacy set and retaining a randomized confirmatory requirement. For investors, this is a better outcome than either extreme: it creates a commercial asset now, but leaves a clear future test that can prove or invalidate the long-term thesis.

09 FDA approval: final label, dosing and safety

On August 6, 2026, FDA granted accelerated approval to TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who experienced disease progression on a PD-1-blocking antibody-based regimen.

How TUDRIQEV is administered

TUDRIQEV is for intratumoral injection only. The recommended volume is 1 mL per centimeter of the tumor’s largest dimension, up to 10 mL across all treated lesions per dose. It is administered every two weeks for eight consecutive doses, beginning at 10⁶ PFU/mL in week one and increasing to 10⁷ PFU/mL thereafter. Nivolumab begins in week three. Deep or visceral lesions require image-guided administration.

Safety in the prescribing information

Serious adverse reactions occurred in 35% of the 140 treated patients. Permanent discontinuation of TUDRIQEV due to adverse reactions occurred in 2.9%. The most common non-laboratory adverse reactions included fatigue, fever, infections, chills, musculoskeletal pain, nausea, diarrhea or colitis, injection-site reaction, headache, cough, influenza-like illness, vomiting, pruritus, arthralgia, asthenia, constipation, decreased appetite, dizziness, skin or superficial infection and dyspnea.

Warnings cover accidental exposure and possible viral transmission, herpetic infection or reactivation, and complications of the injection procedure including hemorrhage, infection and visceral injury such as pneumothorax. These risks are operationally important because the product is a live genetically modified HSV-1 therapy delivered directly into tumors.

10 IGNYTE: full cohort versus the FDA efficacy population

IGNYTE (NCT03767348) is an open-label, multicenter Phase 1/2 study. The registration cohort enrolled 140 adults with anti-PD-1-failed cutaneous melanoma who received RP1, now TUDRIQEV, with nivolumab. Because the trial had no randomized concurrent control, the interpretation of response and the contribution of each combination component became the central regulatory controversy.

The difference is not a clerical inconsistency. FDA focused on whether directly injected target lesions could be used to establish systemic antitumor activity. Restricting the efficacy population to patients with at least one noninjected lesion reduced the sample to 91 and produced the 24.2% ORR used in the label.

The label population remained difficult to treat: 80% had stage IV disease, 54% were PD-L1 negative, 45% had lung lesions, 24% had liver lesions and 7% had brain lesions. All had received at least one prior anti-PD-1-based therapy.

11 IGNYTE-3: the trial that now protects — or threatens — the franchise

IGNYTE-3 (NCT06264180; RP1-104) is the randomized, open-label Phase 3 confirmatory trial required to verify clinical benefit. It compares TUDRIQEV plus nivolumab with physician’s choice in advanced melanoma after progression on anti-PD-1 and anti-CTLA-4 therapy, or when anti-CTLA-4 is not appropriate. Planned enrollment is approximately 400 patients and the primary endpoint is overall survival.

The trial was already recruiting before approval, an important feature under the accelerated-approval framework. The control options include nivolumab plus relatlimab, anti-PD-1 monotherapy or single-agent chemotherapy according to protocol and patient eligibility.

Before approval, an immature unplanned snapshot covering 40 patients was submitted during the regulatory process. FDA considered it too early and methodologically limited to resolve the original BLA dispute. That early look should not be confused with the confirmatory evidence the trial is designed to generate.

After August 6, IGNYTE-3 becomes more than a pipeline catalyst. Enrollment pace, protocol integrity, treatment discontinuations, survival follow-up and any changes to projected readout timing are franchise-level variables. A successful result can convert the regulatory thesis into durable commercial value; failure or material delay can threaten continued approval.

Management guides the primary OS readout in 2030. FDA’s approval letter separately sets study completion for September 2030 and final-report submission for March 2031, with periodic progress reporting. The August 31, 2026 final-protocol deadline is past; the deadline alone is not proof of submission. These are distinct obligations, not a single guaranteed readout date.

The July 15 registry record remains RECRUITING with 400 estimated participants. It lists primary completion September 30, 2030 and overall completion March 31, 2031, while some outcome-description text still references January 2029. The newer FDA letter and August corporate guidance anchor the forward schedule. Registry estimates and previously discussed H2 2027 interim analyses are not a confirmed upcoming readout.

ClinicalTrials.gov · IGNYTE-3 · FDA

12 What accelerated approval means now

Accelerated approval allows FDA to clear a therapy for a serious disease using an endpoint reasonably likely to predict clinical benefit, with that benefit verified after approval. For TUDRIQEV, the approval rests on objective response rate and duration of response.

This is a real marketing authorization, not an expanded-access program or provisional recommendation. Replimune can commercialize TUDRIQEV in the approved U.S. indication, subject to manufacturing, distribution, pharmacovigilance, labeling and post-marketing requirements.

It is also conditional in an economically important sense. Continued approval may depend on verification of benefit in IGNYTE-3. FDA has greater authority under current accelerated-approval rules to require trial progress, enforce reporting and move toward withdrawal if confirmatory obligations are not completed with due diligence or if benefit is not confirmed.

What approval settles

• TUDRIQEV may be marketed in the approved indication.
• The immediate BLA dispute is resolved.
• Replimune becomes commercial stage.
• The broad post-PD-1 label creates a defined U.S. addressable population.

What remains conditional

• Verification of clinical benefit in IGNYTE-3.
• Durability of authorization over the product life cycle.
• Commercial adoption, reimbursement and account readiness.
• Financing the launch and the confirmatory program.

The approval letter also requires CBER lot release before distribution. Manufacturing release, cold-chain handling and pharmacovigilance therefore remain operational requirements alongside commercial account activation.

13 Cash, quarterly burn and the filed going-concern conclusion

The Form 10-Q was filed August 14. Cash, equivalents and short-term investments were $195.3M at June 30 versus $268.9M at March 31. The $73.6M balance decrease is not operating cash burn: the cash-flow statement reports $75.728M used in operations during fiscal Q1 2027. August financing added $141.0M net. Adding that to June liquidity gives $336.3M before subsequent spending and other movements, an illustrative bridge rather than a September cash balance.

Note 1 expressly concludes that the conditions that raised substantial doubt were subsequently alleviated after the August financing. Management forecasts funding for more than twelve months from issuance of the August 14 statements, including commercialization and working capital. This updates the interim accounting conclusion; it does not rewrite the historical FY2026 audit opinion, guarantee cash through the 2030 confirmatory readout or imply profitability. Assumptions about launch costs and receipts can change. No product revenue was recorded through June 30, before approval.

SEC · notes 1, 15 and cash flows

14 Commercial launch after the 55% workforce reduction

Following the April 2026 Complete Response Letter, Replimune reduced its workforce by roughly 55%. The FY2026 10-K states: “Following our reduction in force after receiving the second CRL, we no longer have in-house sales, marketing or commercialization staff.” That sentence was written before the August approval and now becomes a central execution question.

On August 14 management guided product availability within 60 days, approximately by October 13. That historical window was fulfilled by confirmed U.S. availability on October 1, 2026; availability alone does not establish patient starts or revenue. Michelle DiNapoli’s Chief Commercial Officer appointment became effective August 18; the August 19 inducement grant confirms the commercial rebuild. Her prior Deciphera and Genentech experience supports execution, but does not establish a fully staffed field force or launch economics.

The August 6 release calls TUDRIQEV the company’s first commercially available product and introduces ReplimuneConnect Plus, a patient-support program covering access, reimbursement and financial assistance. However, the release did not provide a complete description of the rebuilt commercial organization, launch headcount, field deployment, distribution inventory, list price or near-term revenue guidance.

Management had previously described an initial focus on approximately 150 high-volume accounts, particularly centers with integrated interventional-radiology capability. That concentration can make launch education more efficient, but it also means adoption will depend on a relatively small set of institutions completing pharmacy, biosafety, imaging, reimbursement and scheduling work.

15 Hercules: maturity extended to October 2029

Note 7 states that FDA approval triggered the contractual extension to October 1, 2029, with interest-only payments through September 2029. The prior October 2027 balloon is therefore obsolete as a forward deadline. The June 30 repayment table reflects the earlier reporting-date terms; the subsequent approval and explicit extension in the same note govern the forward description. Funded principal advances total $80M; the facility’s $200M maximum is not cash already received. Additional tranches remain conditional.

Cash interest is the higher of 8.5% or Prime plus 1.75%, plus 1.5% payment-in-kind interest added to principal and a 4.95% end-of-term charge under the agreement. The basic liquidity covenant requires cash covering 35% of secured obligations. After July 1, if principal reaches at least $100M, additional revenue or alternative market-capitalization/cash tests apply: the disclosed alternatives include market capitalization above $1.2B with cash at least 50% of secured obligations, or cash at least 85%. Availability is not unconditional, and nominal liquidity is not all freely deployable. The extension reduces near-term refinancing pressure but does not finance the full confirmatory program.

SEC · note 7

16 August financing, common shares and potential dilution

The August financing comprised 9,701,490 common shares at $12.06 and pre-funded warrants for 2,736,340 shares at $12.0599 plus a $0.0001 exercise price. The quarterly note confirms $141.0M net against $150M gross, superseding the preliminary $140.5M estimate. There is a one-day source discrepancy: note 15 says completed August 10, while the Baker Form 4 identifies an August 11 closing. Both describe the same offering, not two fundraises.

The current cover count is 94,219,634 common shares at August 11, replacing the old June count plus offering arithmetic. June 30 pre-funded warrants covered 14,058,153 shares; adding the August tranche gives 16,794,493 dated warrant equivalents. An illustrative sum with August common shares is 111,014,127, only if no intervening exercises are already included in that count. This is not a verified fully diluted September denominator. June options (12,492,872), restricted/performance stock units (4,825,591) and later awards are separate potential dilution.

No ATM shares were sold in the June quarter. The filing reports $67.9M remaining under the $100M program after FY2026 sales; capacity is not cash or proof of later sales. The July 24 Baker resale amendment is secondary supply, not new corporate proceeds. Separately, the August 14 S-3ASR creates an automatic shelf for future primary securities offerings; registration itself is not issuance. The August 19 DiNapoli inducement award adds 150,000 options at $15.58 and 100,000 RSUs, subject to vesting, rather than immediate common shares sold for cash.

SEC · 10-Q · SEC · S-3ASR · IR · awards

17 RP2 and the rest of the pipeline

RP2’s guided Q1 2027 transition now falls within the greater-than-twelve-month financing forecast from August 14, rather than at the obsolete early-2027 runway boundary. It remains a development milestone, not late-stage efficacy confirmation or independent commercial revenue.

REVEAL NCT06581406 remains RECRUITING in the April 2 registry, with 280 estimated participants and dual OS/PFS primary endpoints. Its estimated January 2030 primary completion is distinct from the company’s Q1 2027 Phase 2/3 transition. Other pipeline statuses above are historical source-dated descriptions, not newly verified recruitment milestones.

18 Red flags and risks after approval

• Accelerated-approval risk. Continued marketing may depend on IGNYTE-3 verifying clinical benefit. Failure, delay or inadequate diligence can lead to restrictions or withdrawal.
• Commercial rebuild risk. The latest 10-K said Replimune no longer had in-house sales, marketing or commercialization staff after the 55% reduction.
• Financing and dilution. The August financing moved the stated runway beyond twelve months, but it did so by issuing equity: the ATM retains capacity, a launch increases working-capital needs, and the confirmatory trial runs to a 2030 primary readout.
• Label-data reset. The approved efficacy set reports 24.2% ORR and 14.1-month median DOR in 91 patients, below the full-cohort figures prominent in earlier investor materials.
• Procedure burden. Repeated injections, imaging guidance, nivolumab infusion, biosafety and multidisciplinary scheduling can restrict adoption outside prepared centers.
• Safety and handling. Serious adverse reactions occurred in 35% of treated patients; warnings include viral exposure, herpetic infection or reactivation and visceral injury.
• Manufacturing and distribution. A live oncolytic virus requires consistent production, cold-chain handling, quality control and reliable delivery. Replimune has limited commercial experience.
• Competition. Amtagvi, checkpoint combinations, targeted therapy for eligible BRAF-mutant disease, clinical trials and future therapies compete for overlapping patients.
• Debt. The Hercules facility remains outstanding, with interest, maturity and covenant considerations that do not disappear after approval.
• The share price can respond sharply to regulatory and commercial news. Such volatility does not itself establish a clinical result or revenue.

19 Upcoming events and obligations

IR · Cantor · IR · guidance · FDA · obligations

20 Assessment, retail sentiment and insider disclosures

Retail discussion reflects opinion and attention; it does not establish a clinical result, regulatory approval or commercial demand.

The August 24 Form 4 records Astley-Sparke’s August 20 gift of 50,000 shares to a donor-advised fund, code G, not a market sale. Hill’s August 17 sale of 9,256 shares at a weighted $14.28, reported August 19, was an irrevocable RSU tax-cover transaction. The August 12 officer sales likewise identify mandatory PSU tax cover. Baker funds purchased the 2,736,340 new pre-funded warrants in the offering; that financing participation should not be confused with open-market purchases or with the unrelated resale registration.

Retail discussion reflects opinion and attention; it does not establish a clinical result, regulatory approval or commercial demand.

21 Sources

Prospectus supplement, Form 424B5, August 10, 2026 — offering size, price, pre-funded warrants, gross and net proceeds, share count and use of proceeds. SEC filing

Form 8-K, filed August 10, 2026 (event of August 9, 2026) — underwriting agreement with Leerink Partners, J.P. Morgan Securities and Cantor Fitzgerald, and terms of the pre-funded warrants. SEC filing

FDA approval announcement, August 6, 2026 — accelerated approval of TUDRIQEV with nivolumab in treatment-resistant advanced cutaneous melanoma. FDA announcement

Replimune approval release, August 6, 2026 — final indication, efficacy population, ORR, DOR, safety, patient-support program and investor-call details. Official company release

TUDRIQEV U.S. Prescribing Information, August 2026 — indication, dosing, administration, warnings, safety and clinical-study efficacy table. Full prescribing information

FDA advisory committee meeting page, July 30, 2026 — agenda, meeting materials, briefing documents, presentations, roster, voting question and conflict-of-interest waiver. FDA meeting page

FDA CTGTAC Voting Question — “Are the efficacy results from IGNYTE evaluable and clinically meaningful?” with Yes, No or Abstain options. FDA voting-question PDF

FDA live advisory committee meeting, July 30, 2026 — final vote observed live: 10 Yes, 3 No, 0 Abstain. Formal minutes or transcript were not yet posted at the time of this update. The webcast is linked from the FDA meeting page.

FDA Briefing Document, BLA 125827 — the agency’s pre-meeting analysis of response assessment, contribution of effect, historical controls, overall survival and the draft voting question. FDA briefing document

Replimune sponsor briefing document — the company’s clinical and regulatory case presented to the committee. Sponsor briefing document

Conflict-of-interest waiver for Hussein Tawbi, July 27, 2026 — limited waiver related to MD Anderson Cancer Center’s participation in IGNYTE-3; the document states that Dr. Tawbi had no affected personal financial interest. FDA waiver PDF

FDA Complete Response Letter, BLA 125827, April 10, 2026 — the full second CRL. FDA CRL PDF

Federal Register — notice and amended notice for docket FDA-2026-N-7231. Federal Register notice

SEC filings, CIK 0001737953 — FY2026 Form 10-K; 8-K filings covering the first and second CRLs, resubmission, class 1 acceptance and Hercules amendment; Form S-3/A filed July 24, 2026, which amended a Baker Brothers resale registration covering 25,103,489 existing shares and registered no additional securities. Replimune EDGAR index

Replimune press releases — May 29 resubmission path, June 26 Class 1 acceptance, June 29 fiscal 2026 results and the July 30 favorable AdCom statement including CEO Sushil Patel’s comments. Replimune investor relations

Replimune, July 30, 2026 — official post-meeting release confirming the 10–3 vote and management’s statement that the company would continue working with FDA ahead of the action date. Official release

ClinicalTrials.gov — IGNYTE NCT03767348; IGNYTE-3 NCT06264180; RP2 uveal melanoma NCT06581406; RP2 HCC NCT05733598; CERPASS NCT04050436. The July 15 IGNYTE-3 record lists September 30, 2030 as estimated primary completion and March 31, 2031 as estimated overall completion; FDA separately requires the final report in March 2031. IGNYTE-3 study record

Journal of Clinical Oncology 43(33):3589-3599 — published IGNYTE registration-cohort efficacy, as cited in the FY2026 10-K.

Reuters, July 28 and July 31, 2026 — reporting on the FDA staff efficacy concerns, the 10–3 panel outcome, the July 31 market reaction and BMO analyst Evan Seigerman’s post-vote assessment. Reuters post-vote report

Barron’s reported a 107% share-price increase following the positive advisory-panel vote on July 31, 2026. This is an attributed historical news report, not the current share price. Barron’s report.

MT Newswires, June 30, 2026 — reported BMO Capital’s earlier upgrade to Outperform from Underperform and target increase to $16 from $1. BMO rating report

Finviz read October 2, 2026: market capitalization 1.28B USD; provider shares 94.22M, float 88.61M, short float 25.68% (22.75M shares short), short ratio 5.33; institutional ownership 103.02%, insider ownership 5.95%. The previous regular-session close was $13.45 on October 1. Provider fields can lag underlying filings; the reading date is not the short settlement date. Provider shares remain distinct from dated SEC shares. Ownership reports may overlap and do not form an exclusive allocation of the capital. Finviz.

SEC · 10-Q August 14 · FDA · approval letter · IR · September 3 · IR · August 19 · SEC · automatic shelf

Finviz read October 2, 2026: market capitalization 1.28B USD; provider shares 94.22M, float 88.61M, short float 25.68% (22.75M shares short), short ratio 5.33; institutional ownership 103.02%, insider ownership 5.95%. The previous regular-session close was $13.45 on October 1. Provider fields can lag underlying filings; the reading date is not the short settlement date. Provider shares remain distinct from dated SEC shares. Ownership reports may overlap and do not form an exclusive allocation of the capital. Finviz.

Related Research On Merlintrader

FDA Showdown Week: Capricor and Replimune face back-to-back AdCom tests — the two panels in the same week.

Capricor Therapeutics (Nasdaq: $CAPR) Stock Hub — the other binary FDA event this week.

FDA U-Turns: Moderna, Sarepta and uniQure lead a year of regulatory reversals — the wider pattern.

The Top Ten Biotech Stocks Right Now — where this sits in the broader catalyst calendar.